Fovea Pharmaceuticals

Fovea discovered and developed innovative drugs for the treatment of retinal diseases such as age-related macular degeneration, retinitis pigmentosa, diabetic retinopathy and macular edema. The company was acquired by sanofi-aventis for up to €370 million in October 2009.